Table 3. Overall survival rate (months) and progression-free survival at different dosages and therapies with TPS PD-L1 ≥ 50% .
Treatment | Overall survival | Progression free survival |
Pembrolizumab 2 mg/kg | 14.9 | 5.0 |
Pembrolizumab 10 mg/kg | 12.7 | 4.0 |
Docetaxel | 8.2 | 4.1 |